Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA<sub>1c</sub> in T2DM.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 34487441.
- Also identified by DOI 10.7326/ACPJ202109210-106.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Giugliano D, Longo M, Caruso P, et al. <b>Feasibility of simplification from a basal-bolus insulin regimen to a fixed-ratio formulation of basal insulin plus a GLP-1RA or to basal insulin plus an SGLT2 inhibitor: BEYOND, a randomized, pragmatic trial.</b> Diabetes Care. 2021;44:1353-60. 33883195.
Medical subject headings
- Diabetes Mellitus, Type 2
- Sodium-Glucose Transporter 2 Inhibitors